US drugmaker: Alzheimer's development can be slowed down | DW News

US drugmaker Eli Lilly says its experimental drug Alzheimer's drug Donanemab can slow down the development of the disease. Patients with the disease will inevitably deteriorate, but the company says that process can be delayed by four to seven months. Eli Lilly wants the Federal Drugs Administration to approve its product. The FDA turned down a request for early approval earlier this year and demanded further trials. The company say those trials show the drug slows the development of Alzheimers in 60% of early stage patients, but also reported significant side-effects. For more on this, we talk to Eric Widera. He's professor of Medicine and clinician-educator in the Division of Geriatrics at the University of California in San Francisco. He also wrote an editorial published alongside that Eli Lilly report in the Journal of the American Medical Association today. #alzheimer #usa #dementia Subscribe: https://www.youtube.com/user/deutschewelleenglish?sub_confirmation=1 For more news go to: http://www.dw.com/en/ Follow DW on social media: ►Facebook: https://www.facebook.com/deutschewellenews/ ►Twitter: https://twitter.com/dwnews ►Instagram: https://www.instagram.com/dwnews ►Twitch: https://www.twitch.tv/dwnews_hangout Für Videos in deutscher Sprache besuchen Sie: https://www.youtube.com/dwdeutsch